|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet. |
| 公司地址
| 3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108 |
| 電話號碼
| +1 734 887-3903 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.esperion.com |
| 員工數量
| 294 |
| Mr. John B. Harlow, Jr |
Chief Commercial Officer |
美元 66.88K |
16/04/2026 |
| Mr. Benjamin O. Looker |
Chief Legal and Corporate Affairs Officer |
-- |
16/04/2026 |
| Mr. Benjamin Halladay |
Chief Financial Officer |
美元 495.83K |
16/04/2026 |
| Mr. Sheldon L. Koenig |
Director, President and Chief Executive Officer |
美元 770.83K |
16/04/2026 |
|
|
| Mr. Robert E. Hoffman, C.P.A. |
Independent Director |
16/04/2026 |
| Mr. Seth H.Z. Fischer |
Independent Director |
16/04/2026 |
| Dr. Craig B. Thompson,M.D. |
Independent Director |
16/04/2026 |
| Ms. Tracy M. Woody |
Independent Director |
16/04/2026 |
| Mr. J. Martin Carroll |
Chairman of the Board |
16/04/2026 |
| Mr. Jay P. Shepard |
Independent Director |
16/04/2026 |
| Mr. Stephen C. Rocamboli |
Independent Director |
16/04/2026 |
| Mr. Sheldon L. Koenig |
Director, President and Chief Executive Officer |
16/04/2026 |
|
|
|
|
